title: Serum periostin in obstructive airways disease.
abstract: Serum periostin is a potential biomarker of response to therapies that target type 2 inflammation in asthma. The objectives of this study were to describe: 1) the distribution of serum periostin levels in adults with symptomatic airflow obstruction; 2) its relationship with other variables, including type 2 biomarkers; and 3) the effect of inhaled corticosteroids on periostin levels.Serum periostin levels were measured in a cross-sectional study exploring phenotypes and biomarkers in 386 patients aged 18-75 years who reported wheeze and breathlessness in the past 12 months. In 49 ICS-naïve patients, periostin levels were measured again after 12 weeks of budesonide (800 μg·day(-1)).The distribution of serum periostin levels was right skewed (mean±sd 57.3±18.6 ng·mL(-1), median (interquartile range) 54.0 (45.1-65.6) ng·mL(-1), range 15.0-164.7 ng·mL(-1)). Periostin was positively associated with exhaled nitric oxide (Spearman's rho=0.22, p<0.001), blood eosinophil count (Spearman's rho=0.21, p<0.001), and total IgE (Spearman's rho=0.14, p=0.007). The Hodges-Lehmann estimator (95% CI) of change in periostin level after ICS therapy was -4.8 (-6.7- -3.2) ng·mL(-1) (p<0.001).These findings provide data on the distribution of serum periostin in adults with symptomatic airflow obstruction, the weak associations between periostin and other type 2 markers, and the reduction in periostin with inhaled corticosteroid therapy.
authors.affiliation: Medical Research Institute of New Zealand, Wellington, New Zealand Capital and Coast District Health Board, Wellington, New Zealand Victoria University of Wellington, Wellington, New Zealand james.fingleton@mrinz.ac.nz.
authors.forename: James
authors.initials: J
authors.lastname: Fingleton
authors.affiliation: Medical Research Institute of New Zealand, Wellington, New Zealand.
authors.forename: Irene
authors.initials: I
authors.lastname: Braithwaite
authors.affiliation: Medical Research Institute of New Zealand, Wellington, New Zealand Hutt Valley District Health Board, Lower Hutt, New Zealand.
authors.forename: Justin
authors.initials: J
authors.lastname: Travers
authors.affiliation: Medical Research Institute of New Zealand, Wellington, New Zealand Capital and Coast District Health Board, Wellington, New Zealand.
authors.forename: Darren
authors.initials: D
authors.lastname: Bowles
authors.affiliation: Medical Research Institute of New Zealand, Wellington, New Zealand.
authors.forename: Rianne
authors.initials: R
authors.lastname: Strik
authors.affiliation: University of Otago Wellington, Wellington, New Zealand.
authors.forename: Rob
authors.initials: R
authors.lastname: Siebers
authors.affiliation: Genentech, San Francisco, CA, USA.
authors.forename: Cecile
authors.initials: C
authors.lastname: Holweg
authors.affiliation: Genentech, San Francisco, CA, USA.
authors.forename: John
authors.initials: J
authors.lastname: Matthews
authors.affiliation: Capital and Coast District Health Board, Wellington, New Zealand University of Otago Wellington, Wellington, New Zealand.
authors.forename: Mark
authors.initials: M
authors.lastname: Weatherall
authors.affiliation: Medical Research Institute of New Zealand, Wellington, New Zealand Capital and Coast District Health Board, Wellington, New Zealand Victoria University of Wellington, Wellington, New Zealand.
authors.forename: Richard
authors.initials: R
authors.lastname: Beasley
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D001249:Asthma / Q000097:blood / Q000188:drug therapy; D019819:Budesonide / Q000008:administration & dosage; D015815:Cell Adhesion Molecules / Q000097:blood*; D003430:Cross-Sectional Studies; D004804:Eosinophils / Q000166:cytology; D045853:Exhalation; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000188:drug therapy; D008173:Lung Diseases, Obstructive / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009520:New Zealand; D009569:Nitric Oxide / Q000032:analysis; D012129:Respiratory Function Tests; D012135:Respiratory Sounds; D012307:Risk Factors; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D015815:Cell Adhesion Molecules; C512835:POSTN protein, human; D009569:Nitric Oxide; D019819:Budesonide